がん免疫療法創薬アウトソーシング市場規模、シェア、動向分析レポート：薬剤タイプ別、がんタイプ別、サービスタイプ別、地域別、セグメント別予測、2023年～2030年

がん免疫療法創薬アウトソーシング市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のがん免疫療法創薬アウトソーシング市場規模は2030年までに25億米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 9.8％で拡大すると予測されています。この市場の主な促進要因は、世界のがんの有病率の増加、製薬企業やバイオテクノロジー企業によるがん研究への投資の増加、がんの高度治療に対する人々の意識の高まりです。

COVID-19パンデミックの初期段階では、がん免疫療法創薬市場の成長が止まっていました。COVID-19に感染し、早急な集中治療と治療を必要とする患者が大量に流入したためです。また、サプライチェーンの混乱、パンデミック予防のための渡航制限、厳しい規制などが、がん免疫療法創薬市場の遅れにつながっています。しかし、製薬企業や規制当局が戦略的手法を採用することで、この影響は大幅に軽減されるであろう。

市場のその他の促進要因としては、社内の研究開発コストと比較して低コストであることから急増している創薬のアウトソーシング需要や、いくつかのメリットを享受できる税額控除の利用が挙げられます。例えば、税務当局との一般的に遭遇する問題が軽減され、製薬会社やバイオテクノロジー企業がCROを利用して世界プロジェクトを効果的に計画できるようになります。また、各国政府もがん治療に積極的に参加し、イニシアチブをとっています。例えば、2022年4月、インド政府はがん治療のための17の病院を立ち上げました。これはタタ・トラストと政府による共同イニシアチブで、安価ながん治療ネットワークを構築することを目的としています。

また、チェックポイント阻害剤、免疫調節剤、腫瘍浸潤リンパ球、CAR-T細胞療法など、がん免疫療法のためのさまざまな新分子や新しい免疫療法の選択肢が開発されています。その他にも、がんに対する有効性を確認するためのパイプラインがまだいくつか進行中です。

がん免疫療法創薬アウトソーシング市場レポート・ハイライト

• モノクローナル抗体分野が市場を独占し、2022年には63.0%の最大売上シェアを占めました。この成長は、高い有効性と規制当局による承認の増加によるものです。
• リードスクリーニングおよび特性評価セグメントは、予測期間中に最も速いCAGRで成長すると予想されます。これは、このセグメントで効果的なアッセイにかかる時間を短縮する新しい効果的な方法が増加しているためです。
• 肺がんセグメントは、2022年に24.5%と最大の収益シェアを占めました。この増加は、このがん種に有効な免疫療法が多数普及しているためです。
• 北米が市場を独占し、2022年には36.2%の売上シェアを占めました。これは、同地域における新技術への需要の高まりとがんの罹患率の増加によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 がん免疫療法創薬アウトソーシング市場変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• がん免疫療法創薬アウトソーシング市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 がん免疫療法創薬アウトソーシング：薬剤タイプの推定・動向分析

• がん免疫療法創薬アウトソーシング市場：重要なポイント
• がん免疫療法創薬アウトソーシング市場：動向と市場シェア分析、2022年および2030年
• モノクローナル抗体
• 免疫調節剤
• がんワクチンと腫瘍溶解性ウイルス療法
• その他

第5章 がん免疫療法創薬アウトソーシング：サービスタイプの推定・動向分析

• がん免疫療法創薬アウトソーシング市場：重要なポイント
• がん免疫療法創薬アウトソーシング市場：動向と市場シェア分析、2022年および2030年
• ターゲットの特定と検証
• リードのスクリーニングと特性評価
• 細胞ベースのアッセイ

第6章 がん免疫療法の創薬アウトソーシング：がんタイプの推定・動向分析

• がん免疫療法創薬アウトソーシング市場：重要なポイント
• がん免疫療法創薬アウトソーシング市場：動向と市場シェア分析、2022年および2030年
• 肺
• 胸
• 結腸直腸
• 黒色腫
• 前立腺
• 頭と首
• 卵巣
• 膵臓

第7章 がん免疫療法創薬アウトソーシング市場：地域の推定・動向分析

• 地域別の展望
• 地域別がん免疫療法創薬アウトソーシング市場：重要なポイント
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • Explicyte Immuno-Oncology
  • Aquila Biomedical
  • Horizon Discovery Group plc
  • Crown Bioscience Inc.
  • Promega Corporation
  • HD Co. Ltd.
  • BPS Biosciences Inc.
  • Gen script Biotech Corporation
  • Celentyx Ltd.
  • ImmuneXperts SA
  • Personalis
  • STC Biologics
  • Molecular Imaging Inc. (MI Bioresearch Inc.)
  • Covance, Inc.

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 3 North America cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 4 North America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 5 North America cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 6 U.S. cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 7 U.S. cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 8 U.S. cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 9 Canada cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 10 Canada cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 11 Canada cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 12 Europe cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 13 Europe cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 14 Europe cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 15 Europe cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 16 Germany cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 17 Germany cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 18 Germany cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 19 UK cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 20 UK cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 21 UK cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 22 France cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 23 France cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 24 France cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 25 Italy cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 26 Italy cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 27 Italy cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 28 Spain cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 29 Spain cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 30 Spain cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 31 Sweden cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 32 Sweden cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 33 Sweden cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 34 Norway cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 35 Norway cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 36 Norway cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 37 Denmark cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 38 Denmark cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 39 Denmark cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 44 China cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 45 China cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 46 China cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 47 Japan cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 48 Japan cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 49 Japan cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 50 India cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 51 India cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 52 India cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 53 Australia cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 54 Australia cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 55 Australia cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 56 Thailand cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 57 Thailand cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 58 Thailand cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 59 South Korea cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 60 South Korea cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 61 South Korea cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 62 Latin America cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 63 Latin America cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 64 Latin America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 65 Latin America cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 66 Brazil cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 67 Brazil cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 68 Brazil cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 69 Mexico cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 70 Mexico cancer immunotherapy drug discovery outsourcing market, by material, 2018 - 2030 (USD Million)
• Table 71 Mexico cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 72 Argentina cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 73 Argentina cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 74 Argentina cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 75 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by type, 2018 - 2030 (USD Million)
• Table 76 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 77 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 78 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 79 South Africa cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 80 South Africa cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 81 South Africa cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 85 UAE cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 86 UAE cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 87 UAE cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 88 Kuwait cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 89 Kuwait cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 90 Kuwait cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)

List of Figure

Fig. 1 Market research process

Fig. 2 Data triangulation techniques

Fig. 3 Primary research pattern

Fig. 4 Market research approaches

Fig. 5 Value-chain-based sizing & forecasting

Fig. 6 QFD modeling for market share assessment

Fig. 7 Market formulation & validation

Fig. 8 Cancer immunotherapy drug discovery outsourcing: Market outlook

Fig. 9 Cancer immunotherapy drug discovery outsourcing: Competitive insights

Fig. 10 Parent market outlook

Fig. 11 Related/ancillary market outlook

Fig. 12 Penetration and growth prospect mapping

Fig. 13 Industry value chain analysis

Fig. 14 Cancer immunotherapy drug discovery outsourcing market driver impact

Fig. 15 Cancer immunotherapy drug discovery outsourcing market restraint impact

Fig. 16 Cancer immunotherapy drug discovery outsourcing market strategic initiatives analysis

Fig. 17 Cancer immunotherapy drug discovery outsourcing market: Drug type movement analysis

Fig. 18 Cancer immunotherapy drug discovery outsourcing market: drug type outlook and key takeaways

Fig. 19 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 20 Immunomodulators market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 21 Cancer vaccines and oncolytic viral therapy market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 23 Cancer immunotherapy drug discovery outsourcing market: Service type movement analysis

Fig. 24 Cancer immunotherapy drug discovery outsourcing market: Service type outlook and key takeaways

Fig. 25 Target identification and validation market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 26 Lead screening and characterization market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 27 Cell-based assays market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 28 Cancer immunotherapy drug discovery outsourcing market: Cancer type movement analysis

Fig. 29 Cancer immunotherapy drug discovery outsourcing market: Cancer type outlook and key takeaways

Fig. 30 Lung market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 31 Breast market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 32 Colorectal market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 33 Melanoma market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 34 Prostate market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 35 Head and neck market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 36 Ovarian market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 37 Pancreatic market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 38 Global cancer immunotherapy drug discovery outsourcing market: Regional movement analysis

Fig. 39 Global cancer immunotherapy drug discovery outsourcing market: Regional outlook and key takeaways

Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 44 UK market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 46 France market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 47 Italy market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 48 Spain market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 53 Japan market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 55 India market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 56 Australia market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 58 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 59 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 60 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 61 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 62 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 63 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 64 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 65 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 66 UAE market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 67 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Cancer Immunotherapy Drug Discovery Outsourcing Market Growth & Trends:

The global cancer immunotherapy drug discovery outsourcing market size is expected to reach USD 2.5 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 9.8% from 2023 to 2030. The main drivers of this market are the increasing prevalence of cancer Worldwide, increasing investment by pharmaceutical and biotechnology companies in cancer research, and the rise in awareness among people for advanced treatment of cancer.

In the early stages of the COVID-19 pandemic, there was a halt in the growth of the cancer immunotherapy drug discovery market. This decrease in cancer immunotherapy drug discovery is due to the influx of a large number of patients that are infected with COVID-19 and require immediate intensive care and treatment. Also, disruptions in the supply chain, travel restrictions to prevent pandemics, and strict regulations have resulted in delays in the cancer immunotherapy drug discovery market. However, this impact will be significantly reduced by adopting strategic methods taken by pharmaceutical companies and regulatory authorities.

Other drivers of the market are the rising demand for outsourcing of drug discovery, which is increasing rapidly due to low cost as compared to in-house R&D costs, and the use of a tax credit that allows several benefits. For instance, reduces problems that are generally encountered with taxation authorities and it allows pharmaceutical and biotechnology companies to plan effectively their global projects with CRO. Also, the governments are actively participating and taking initiatives for cancer treatment. For instance, in April 2022, the government of India launched 17 hospitals for the treatment of cancer. This is a joint initiative taken by Tata trust and the government, to create an affordable cancer care network.

Also, there is the development of various new molecules for cancer immunotherapy and new immunotherapeutic options such as checkpoint inhibitors, immunomodulators, tumor-infiltrating lymphocytes, and CAR-T cell therapy. Several others are still in the pipeline to check their efficacy against cancer.

Cancer Immunotherapy Drug Discovery Outsourcing Market Report Highlights:

• The monoclonal antibodies segment dominated the market and accounted for the largest revenue share of 63.0% in 2022. This growth is due to high efficacy and a rise in regulatory approvals
• The lead screening and characterization segment is expected to grow at the fastest CAGR during the forecast period. This is due to a rise in new and effective ways to decrease the time for effective assays in this segment
• The lung cancer segment accounted for the largest revenue share of 24.5% in 2022. This rise is due to the large number of prevalent effective immunotherapies for this cancer type
• North America dominated the market and accounted for a revenue share of 36.2% in 2022. This is due to a rise in demand for new technologies and an increasing incidence of cancer in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Service type
  • 1.1.2. Cancer type
  • 1.1.3. Drug type
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service type outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. Drug type outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Drug Discovery Outsourcing: Drug Type Estimates & Trend Analysis

• 4.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 4.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Monoclonal Antibodies
  • 4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Immunomodulators
  • 4.4.1. Immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Cancer Vaccines and Oncolytic Viral Therapy
  • 4.5.1. Cancer vaccines and oncolytic viral therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cancer Immunotherapy Drug Discovery Outsourcing: Service Type Estimates & Trend Analysis

• 5.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 5.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Target Identification and Validation
  • 5.3.1. Target identification and validation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Lead Screening and Characterization
  • 5.4.1. Lead screening and characterization market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Cell-based Assays
  • 5.5.1. Cell-based assays market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cancer Immunotherapy Drug Discovery Outsourcing: Cancer Type Estimates & Trend Analysis

• 6.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 6.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Lung
  • 6.3.1. Lung market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Breast
  • 6.4.1. Breast market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Colorectal
  • 6.5.1. Colorectal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Melanoma
  • 6.6.1. Melanoma market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Prostate
  • 6.7.1. Prostate market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Head & Neck
  • 6.8.1. Head & Neck market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Ovarian
  • 6.9.1. Ovarian market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.10. Pancreatic
  • 6.10.1. Pancreatic market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Outlook
• 7.2. Cancer Immunotherapy Drug Discovery Outsourcing Market by Region: Key Takeaway
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. France
    • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.6. Sweden
    • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. China
    • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. India
    • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. MEA
  • 7.7.1. Saudi Arabia
    • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Market Participant Categorization
  • 8.2.1. Explicyte Immuno-Oncology
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Aquila Biomedical
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Horizon Discovery Group plc
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Crown Bioscience Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Promega Corporation
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. HD Co. Ltd.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. BPS Biosciences Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Gen script Biotech Corporation
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Celentyx Ltd.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. ImmuneXperts SA
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Personalis
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. STC Biologics
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives
  • 8.2.13. Molecular Imaging Inc. (MI Bioresearch Inc.)
    • 8.2.13.1. Company overview
    • 8.2.13.2. Financial performance
    • 8.2.13.3. Product benchmarking
    • 8.2.13.4. Strategic initiatives
  • 8.2.14. Covance, Inc.
    • 8.2.14.1. Company overview
    • 8.2.14.2. Financial performance
    • 8.2.14.3. Product benchmarking
    • 8.2.14.4. Strategic initiatives